Non-immunogenic staphylokinase
Проводит Supergene, LLC
Страница компанииAn Open, Prospective, Non-interventional, Multicentre, Controlled Study of Safety and Efficacy of the Thrombolysis With the Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke (FORPI Registry)
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT06707987/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 23250 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (02.2025) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 4 · невключение: 29
Критерии включения
- Men and women aged 18 years and older.
- Verified diagnosis of acute ischemic stroke.
- The time from the symptoms onset is no more than 4.5 hours.
- Thrombolysis with the non-immunogenic staphylokinase, 10 mg as a single intravenous bolus.
Критерии невключения
- The time from the symptoms onset is more than 4.5 hours or the time of the symptoms onset is unknown.
- Increased sensitivity to the non-immunogenic staphylokinase.
- Systolic blood pressure above 185 mm Hg or diastolic blood pressure above 110 mm Hg or the need in the drug administration to reduce blood pressure to these levels.
- Neuroimaging (CT, MRI) signs of intracranial hemorrhage, brain tumors, arteriovenous malformation, brain abscess, aneurysm of cerebral vessels.
- Surgery on the brain or spinal cord.
- Suspicion of subarachnoid hemorrhage.
- Signs of severe stroke: clinical signs (stroke scale NIH > 25), neuroimaging (according to CT of the brain and / or MRI of the brain in the DWI, the ischemia focuses on the territory of more than 1/3 of the CMA pool).
- Simultaneous reception of oral anticoagulants, for example, warfarin with INR> 1.3.
- The use of direct anticoagulants (heparin, heparinoids) in the preceding stroke of 48 h with APTT values above the norm.
- Prior stroke or severe head injury within 3 months.
- Significant regression of neurological symptoms during the observation of the patient before thrombolysis.
- Hemorrhagic stroke or stroke, unspecified in history.
- Strokes of any genesis in the history of a patient with diabetes mellitus.
- Gastrointestinal bleeding or bleeding from the genitourinary system in the last 3 weeks. Confirmed exacerbations of gastric ulcer and duodenal ulcer during the last 3 months.
- Extensive bleeding now or within the previous 6 months.
- Severe liver disease, including liver failure, cirrhosis, portal hypertension (with varicose veins of the esophagus), active hepatitis.
- Acute pancreatitis.
- Bacterial endocarditis, pericarditis.
- Aneurysms of arteries, malformations of arteries and veins. Suspicion of exfoliating aortic aneurysm.
- Neoplasms with an increased risk of bleeding.
- Large operations or severe injuries within the last 14 days, minor surgery or invasive manipulation in the last 10 days.
- Puncture of uncompensated arteries and veins during the last 7 days.
- Prolonged or traumatic cardiopulmonary resuscitation (more than 2 min).
- Pregnancy, obstetrics, 10 days after birth.
- The number of platelets is less than 100,000 / μL.
- Blood glucose less than 2.7 mmol / L or more than 22.0 mmol / L.
- Hemorrhagic diathesis, including renal and hepatic insufficiency.
- Data on bleeding or acute trauma (fracture) at the time of examination.
- Seizures in the onset of the disease, if there is no certainty that the seizure is a clinical manifestation of acute ischemic stroke with a postictal residual deficiency.
Источник: ClinicalTrials.gov, NCT06707987 · запись обновлена в реестре 5 декабря 2025.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 3
- Modified Rankin Scale (mRS) score of 0-2 on day 90 after drug administration — day 90 after drug administration
Цель исследования
The aim of FORPI Registry is to study the safety and efficacy of the non-immunogenic staphylokinase in patients with acute ischemic stroke in routine clinical practice.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT06707987 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.